• Profile
Close

Testosterone therapy in relation to prostate cancer in a US commercial insurance claims database

Cancer Epidemiology, Biomarkers & Prevention Dec 10, 2019

Cook MB, Beachler DC, Parlett LE, et al. - Using a large US commercial insurance research database, experts ascertained if testosterone therapy (TT) alters prostate cancer risk. During 2007 to 2015, men ages 30 years or greater who were new users of TT from the HealthCore Integrated Research Database were selected. Findings revealed that the adjusted prostate cancer IRR was 0.77 when comparing TT with the unexposed group and 0.85 in comparison with the phosphodiesterase type 5 inhibitor (PDE5i) group. Compared with the unexposed or PDE5i comparison groups, men who received TT did not have a higher rate of prostate cancer. The inverse association of TT with prostate cancer can result from residual confounding, contraindication bias, or undefined biological effect.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay